Varian gains more worldwide sites for RapidArc system

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Neoadjuvant radiotherapy prior to surgery was associated with a 3-year OS rate of 88.5% in patients with locally advanced rectal cancer.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Jorge E. Cortes, MD

Taking Stock of Immune Effector Cell Therapy Developments in GI Cancers

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Raed M. Al-Rajabi, MD, discussed the state of immune effector cell therapy for GI malignancies following a presentation he gave at the 2025 ICE-T Congress.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Raed M. Al-Rajabi, MD, discussed the state of immune effector cell therapy for GI malignancies following a presentation he gave at the 2025 ICE-T Congress.

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP

October 6th 2025

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

Russ Conroy

Neoadjuvant Radiotherapy Improves OS With Trade-Off in Rectal Cancer

Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

Related Content

Tim Cortese

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Neoadjuvant radiotherapy prior to surgery was associated with a 3-year OS rate of 88.5% in patients with locally advanced rectal cancer.

Jorge E. Cortes, MD

Taking Stock of Immune Effector Cell Therapy Developments in GI Cancers

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

Raed M. Al-Rajabi, MD, discussed the state of immune effector cell therapy for GI malignancies following a presentation he gave at the 2025 ICE-T Congress.

Brooke Adams, PharmD, BCOP;Natalie Brumwell, PharmD, BCOP;Bryant A. Clemons, PharmD, BCOP

October 6th 2025

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Russ Conroy